7:19 AM
 | 
May 17, 2018
 |  BC Extra  |  Clinical News

Jounce sags after ICOS mAb readout

Jounce Therapeutics Inc. (NASDAQ:JNCE) lost $6.22 (35%) to $11.45 Thursday after reporting data from the Phase I/II ICONIC trial evaluating the company's inducible T cell co-stimulator (ICOS) agonist mAb JTX-2011 to treat advanced solid tumors. The data were released late Wednesday in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in...

Read the full 260 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >